Loading…
← CockpitCompetitor Analysis › NEPHROPLUS.NS Nephrocare Health Services LimitedOpen in the cockpit ↗

Nephrocare Health Services LimitedNEPHROPLUS.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Medical/Nursing Services
Momentum neutral 52
Mkt cap
$702M
US dollars, full cap
Free float
22%
of shares outstanding
$/day
$908,736
20-day average traded
Fwd P/E
48.8×
forward earnings
ROIC−WACC
-0.3 pp
WACC 12.6%
Hurdle
+5 pp
Req g minus delivered
Next earnings
105 days
3 Mar 2027
Close · INR₹653.00
1D-2.2%
1W+3.6%
1M+6.8%
3M-6.6%
6M+0.5%
YTD+39.3%
1Yn/a
ATR %3.8%
Beta0.57
52w lowhigh16.4% off high

What Nephrocare Health Services does

Employees: 3,401

Nephrocare Health Services at a glance

Size Nephrocare Health Services (NEPHROPLUS.NS) is an India Health Care company (Medical/Nursing Services) with a market value of $702M, the 723rd largest of 1,066 India companies the cockpit tracks. Shares closed at ₹653.00 on 18 Nov 2026.

Performance Over six months the shares gained 0.5%, against -8.6% for the median peer and +3.8% for the India market (cap-weighted) — 9th highest of 21 in its peer set.

Growth Revenue grew 32.9% over the last twelve months (peer median +5.2%); the operating margin is 13.1% (peer median 7.5%).

Valuation It trades at 48.8× forward earnings against a peer median of 17.4× (2nd most expensive of 16).

Price implies For today's price to make sense, revenue must grow about 37% a year for seven years (Req g). Recent delivered growth is +32%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.3 points below its cost of capital (12.6% WACC).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

9010011012021 May 202621 Aug 202618 Nov 2026NEPHROPLUS.NS 106Peer median 92
Six months, rebased to 100: Nephrocare Health Services against the median of its 20 peers (local-currency closes).

Nephrocare Health Services financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹11.1B₹9.97B₹7.50B₹5.57B₹4.37B
Revenue growth—+33%+35%+27%—
Gross profit₹3.65B₹2.88B₹1.73B₹1.06B₹537M
EBITDA₹2.46B₹2.27B₹1.63B₹945M₹486M
Net income₹1.28B₹768M₹671M₹351M-₹118M
Free cash flown/a₹1.03B₹298M-₹141M-₹699M
Capital expendituren/a₹1.19B₹1.01B₹800M₹737M
Total debt₹1.49B₹797M₹2.58B₹2.68B₹2.14B

Quarterly statements and history in the cockpit →

Nephrocare Health Services competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%FLGTGMRSWELL1951195940TTALOTHYROCAREDNA4694301060REGAHCO688315127120SRTAGDRXACLNUTXIDXJSLLNEPHROPLUS.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Nephrocare Health Services is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×25×50×75×GMRSWELL1951195940THYROCARE4694688315SRTANUTXIDXJSLLNEPHROPLUS.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Nephrocare Health Services is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%0%100%200%GMRSWELL1951195940THYROCARE4694301060NUTXJSLLNEPHROPLUS.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Nephrocare Health Services is the large dot.

Nephrocare Health Services competitors and peer comparison

How Nephrocare Health Services compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Nephrocare Health Services against its 20 peers (data as of 18 Nov 2026)
MeasureNEPHROPLUS.NSPeer medianRank in peer set
1-month return+6.8%-1.8%5th highest of 21
6-month return+0.5%-8.6%9th highest of 21
Distance from 52-week high-16.4%-30.8%5th highest of 21
Revenue growth (TTM)+32.9%+5.2%3rd highest of 21
Operating margin13.1%7.5%5th highest of 21
Forward P/E48.8×17.4×2nd most expensive of 16
Growth the price implies (Req g, 7 yrs)36.6%6.8%most demanding of 17
Growth delivered (Del g)+31.6%+11.5%4th highest of 17
Hurdle (Req g minus delivered)+5.0 pp-9.1 pp4th most demanding of 17
ROIC minus cost of capital-0.3 pp-0.1 pp10th lowest of 20
EV / EBITDA25.5×7.7×2nd most expensive of 15
Net debt / EBITDA-1.2×1.6×4th least indebted of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Nephrocare Health Services NEPHROPLUS.NSIndia$702M+1%+33%13%48.8×36.6%+31.6%
Fulgent Genetics FLGTUnited States$702M+53%+5%-38%n/an/an/a
GMR Solutions GMRSUnited States$714M-8%-4%14%5.9×-19.6%-4.0%
WELL Health Technologies WELL.TOCanada$661M-9%+29%6%10.1×10.1%+94.5%
Jinxin Fertility 1951.HKHong Kong$758M-4%+7%11%23.1×17.8%+12.4%
HK inno.N 195940.KSSouth Korea$783M-28%+7%12%12.3×-4.7%+12.2%
Terveystalo Oy TTALO.HEFinland$832M-26%-8%8%10.7×-5.1%+5.3%
Thyrocare Technologies THYROCARE.NSIndia$858M+7%+22%26%36.0×28.5%+10.9%
Ginkgo Bioworks DNAUnited States$547M+9%-44%-242%n/an/an/a
BML 4694.TJapan$932M+12%+4%7%19.8×-9.0%+1.6%
Shanghai Labway Clinical Laboratory 301060.SZChina$518M-17%-19%6%n/a5.9%+3.2%
Regis Healthcare REG.AXAustralia$962M-28%+17%4%25.3×13.3%+14.4%
AdaptHealth AHCOUnited States$1.01B-30%-3%3%n/a16.8%+25.2%
Novogene 688315.SSChina$1.01B+13%+6%7%44.8×13.9%+8.2%
JS Link 127120.KSSouth Korea$458M-62%+39%-83%n/an/an/a
Strata Critical Medical SRTAUnited States$443M-10%+23%-4%86.3×n/an/a
GoodRx GDRXUnited States$1.15B+33%-2%12%10.6×6.3%+7.7%
Australian Clinical Labs ACL.AXAustralia$418M+68%-1%8%17.8×4.3%+2.6%
Nutex Health NUTXUnited States$1.19B+42%-19%39%6.5×-18.0%+253.5%
Integral Diagnostics IDX.AXAustralia$413M-22%+26%9%14.7×7.8%+17.7%
Jeena Sikho Lifecare JSLL.NSIndia$394M-55%+135%32%17.4×7.3%+42.6%

Questions

Which companies are Nephrocare Health Services's closest peers?
The cockpit's peer set: Fulgent Genetics (FLGT), GMR Solutions (GMRS), WELL Health Technologies (WELL.TO), Jinxin Fertility (1951.HK), HK inno.N (195940.KS), Terveystalo Oy (TTALO.HE), Thyrocare Technologies (THYROCARE.NS), Ginkgo Bioworks (DNA).
Is Nephrocare Health Services expensive compared with its peers?
On forward p/e it trades at 48.8× against a peer median of 17.4×, 2nd most expensive of 16 in its peer set. For today's price to make sense, revenue must grow about 37% a year for seven years (Req g). Recent delivered growth is +32%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Nephrocare Health Services stock performed?
Over six months to 18 Nov 2026 the shares returned +0.5% against -8.6% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.